Request Demo

Last update 08 May 2025

Nuclear Research Center for Agriculture & Medicine

Company|Iran

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

100 Clinical Results associated with Nuclear Research Center for Agriculture & Medicine

0 Patents (Medical) associated with Nuclear Research Center for Agriculture & Medicine

Literatures (Medical) associated with Nuclear Research Center for Agriculture & Medicine

01 Oct 2008·Radiochemistry

Using computer simulation techniques to design a tellurium-123 target for 123I production

Author: Moghaddam, K. K. ; Sadeghi, M. ; Kakavand, T. ; Ghasemi, R.

The production of ¹²³I from ¹²³Te by the ¹²³Te(p, n)¹²³I reaction at various target enrichments (99.9, 91, 85.4, and 70.1%) was simulated using ALICE and SRIM programs.The ¹²³I production feasibility by the above reaction was evaluated.The calculations give more accurate results for p beam energy of <30 MeV.The cross sections of all Te reactions with p were calculated at 0-30 MeV p beam energy with ALICE program, and the yield of ¹²³I was calculated by anal. methods.The prediction for ¹²³I production via bombardment of ¹²³Te (99.9%) with a p beam energy of 5-15 MeV is ∼7.2 mCi μA^-1 h^-1.

01 Jul 2008·Radiochimica Acta

Radiochemical studies relevant to the no-carrier-added production of ^61,64Cu at a cyclotron

Author: Tenreiro, C. ; Amiri, M. ; Avila, M. ; Sadeghi, M. ; Roshanfarzad, P.

Copper-64 (t½ = 12.7 h) is a promising cancer treatment radiotherapy agent and combines positron emission tomography (PET). It was produced utilizing the 64Ni(p,n) 64Cu nuclear reaction channel. Natural nickel was electroplated successfully, 48 μm thick, onto a gold-coated copper backing slab. Bombardment of nickel plated target was performed with 16 MeV protons at a current of 200 μA. Copper-64 together with copper-61 was separated from Ni and other non-isotopic impurities by ion exchange chromatography. The method of separation of radiocopper has been improved.

01 Nov 2007·Radiochimica Acta

Development of [²⁰¹Tl](III)-DTPA-human polyclonal antibody complex for inflammation detection

Author: Tavakoli, M. B. ; Khorrami, A. ; Jalilian, A. R. ; Kamali-Dehghan, M. ; Kamrani, Y. Y.

Thallium-201 (T1/2=3.04 d) in Tl+ form was converted to Tl3+ cation in presence of O3 in 6 M HCl controlled by RTLC/gel electrophoresis methods and used in the labeling of human polyclonal antibody (HIgG) after conjugation with freshly prepared cyclic DTPA-dianhydride. The best results of the conjugation were obtained by the addition of 1 mL of a HIgG pharmaceutical solution (5 mg/ml, in phosphate buffer, pH=7) to a glass tube pre-coated with DTPA-dianhydride (0.01 mg) at 25 °C with continuous mild stirring for 30 min. The final isotonic [201Tl](III)-DTPA-HIgG complex was checked by radio-TLC using several solvent systems to ensure the formation of only one species followed by filtration through a 0.22 μ filter (specific activity= 33.7 TBq/mM, radiochemical purity >95%). Preliminary bio-distribution studies in normal and inflammation-bearing rats were performed. The target/skin and target/blood ratios were 4 and 6 after 28 h respectively, showing the selectivity of the radiopharmaceutical for the inflammatory lesions.

100 Deals associated with Nuclear Research Center for Agriculture & Medicine

100 Translational Medicine associated with Nuclear Research Center for Agriculture & Medicine

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 03 Mar 2026

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nuclear Research Center for Agriculture & Medicine

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 03 Mar 2026

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing